Key result
Lower HDL-C levels are independently linked to higher cardiovascular, cancer, and non-cardiovascular mortality.
Answers are grounded in this paper and cite their sources.
Initial observational studies have identified high-density lipoprotein cholesterol (HDL-C) as an independent predictor of cardiovascular (CV) risk, even in patients on optimal statin therapy. However, the notion that higher HDL-C is better, has been seriously challenged by the results from several recent clinical and genetic trials. Data from the CANHEART study serve to clarify the relation between HDL-C and cause-specific mortality. Individuals with lower HDL-C levels were independently associated with higher risk of CV, cancer, and non-CV/non-cancer mortality compared with individuals in the reference ranges of HDL-C levels. Given the similarities in associations between HDL-C and CV as swell as non-CV outcomes, it is likely that HDL-C level serve as a marker of risk rather than a causal CV specific risk factor.
No takes yet. Share an insight, caveat, or question.
Hassan et al. (2017) conducted an editorial in Cardiovascular and cause-specific mortality risk. Lower HDL-C levels vs. Reference ranges of HDL-C levels was evaluated on Cause-specific mortality (cardiovascular, cancer, and non-cardiovascular/non-cancer mortality). Lower HDL-C levels were independently associated with higher risk of cardiovascular, cancer, and non-cardiovascular/non-cancer mortality compared with reference ranges.
Synapse has enriched 10 related papers. Consider them for comparative context: